Overview of Diclofenac STADA

Property	Description
Active Ingredient	Diclofenac (Sodium or Potassium Salt)
Form	Tablets, Capsules, Gel, Solution
Pharmacological Class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use	Relief of Pain, Inflammation, and Fever
Origin	Synthetic (Phenylacetic Acid Derivative)

What Type of Medicine is Diclofenac STADA?

Diclofenac STADA is a branded preparation whose active component is the established substance diclofenac, which is pharmacologically categorized as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This synthetic compound, chemically classified as a phenylacetic acid derivative, is globally recognized in clinical practice for its anti-inflammatory properties. Diclofenac is generally considered a monopreparation, confirming that the single, primary therapeutic effect is derived exclusively from the diclofenac component, which may be formulated as its sodium or potassium salt.

Composition and Available Forms of Diclofenac STADA

The active ingredient is diclofenac, a widely used compound developed for its three primary actions: anti-inflammatory, analgesic, and antipyretic. Diclofenac STADA is distributed in several dosage forms suitable for different routes of administration, including tablets (often as gastro-resistant formats for oral use), capsules, solution for injection, and gel or patches for topical application. The availability of diverse forms, from systemic oral tablets to localized topical gels, allows for administration based on the specific site of discomfort. The specific salt used, such as diclofenac sodium or diclofenac potassium, is selected to optimize the rate at which the active substance is absorbed by the body.

What is the General Purpose of Diclofenac STADA?

The general purpose of this medicine is to interrupt the biological processes that create the substances responsible for pain and swelling. Diclofenac achieves this by limiting the production of prostaglandins, which are chemical messengers central to signaling pain, causing inflammation, and contributing to fever. Its overall therapeutic effect, therefore, is to provide effective relief from pain, reduce associated swelling, and lower elevated body temperature, making it a reliable foundation drug within the NSAID class.

What side effects are possible with Diclofenac STADA?

Possible Side Effects and Safety Information

Diclofenac, like other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), has an officially documented safety profile categorized by the frequency and body system affected. These classifications reflect how government regulatory documents organize and communicate the medicine's risks.

Commonly Documented Adverse Reactions

Side effects categorized as Common (affecting up to 1 in 10 users) primarily involve Gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, indigestion, and flatulence. Effects on the Nervous system may include headache and dizziness. An increase in liver transaminases has also been officially listed as a common effect.

Serious Adverse Reactions and Safety Constraints

Regulatory warnings highlight the risk of Serious Adverse Reactions. These include potentially fatal Cardiovascular Thrombotic Events (such as myocardial infarction or stroke) and severe Gastrointestinal Events (bleeding, ulceration, or perforation), which can occur at any point during treatment, often without prior warning symptoms. Rare reactions include severe dermatological conditions like Stevens-Johnson syndrome.

Risk minimization notes from regulatory agencies state that the risk of serious events is associated with the duration of use and may be dose-dependent. Use is generally contraindicated in patients with established Ischaemic Heart Disease, Congestive Heart Failure (NYHA Class II–IV), or a history of recurrent peptic ulcer/hemorrhage. Older adults are recognized as having an increased risk for serious gastrointestinal and cardiovascular adverse events.

Overdose and Emergency Response

Overdose and when to seek help

This profile synthesizes official overdose information strictly documented in governmental regulatory sources.

Overdose scope

Feature	Official Regulatory Statement (Label-Based)
Documented overdose presentations	Gastrointestinal symptoms (e.g., epigastric pain, nausea, vomiting); CNS effects (e.g., lethargy, dizziness, tinnitus). Severe cases may include seizures or coma.
Physiological systems affected	Gastrointestinal (bleeding, perforation); Renal (acute renal failure); CNS (respiratory depression); Cardiovascular (hypotension).
Dose-related or exposure-related factors	Gastric decontamination (e.g., activated charcoal) may be considered if administered within four hours of ingestion.
Population-specific overdose notes	Elderly patients face increased risk for serious gastrointestinal events (bleeding/perforation) during overdose.
Emergency-response statements	Management is primarily symptomatic and supportive. No specific antidote is known.
When immediate medical help is required	Seek immediate medical attention or contact a Poison Control Center immediately. Also seek emergency help for signs of anaphylaxis (severe allergic reaction).

Overdose classifications (high-level)

Classification Aspect	Official Regulatory Statement
Severity classification	Overdose may lead to severe or life-threatening outcomes, including acute renal failure and fatal GI perforation.
Overdose-context constraints	Hospital monitoring and specific procedures, such as monitoring vital signs, may be required.

Resulting overdose structure

Official overdose statements:

Regulatory documents define overdose by initial GI/CNS symptoms but emphasize the risk of severe outcomes like acute renal failure and seizures.
Immediate medical attention or Poison Control contact is mandatory upon suspected overdose or for signs of anaphylaxis.
Management is symptomatic and supportive as no specific antidote is known, often requiring hospital monitoring.

Connection to the overall overdose profile (3 sentences):

The official overdose profile is defined by a range of documented manifestations, which rapidly escalate to severe systemic risks affecting the renal and gastrointestinal systems. Due to the lack of a known specific antidote, regulatory guidance mandates symptomatic and supportive care under medical supervision. The core practical implication is the explicit requirement to seek immediate medical attention when overdose is suspected.

Therapeutic Uses of Diclofenac STADA

What Diclofenac STADA Treats: Main Uses and Benefits

Diclofenac STADA is commonly used to provide symptomatic relief across multiple domains where symptoms related to inflammatory or irritative states create noticeable interference with daily stability. This medicine is commonly used to relieve pain, tenderness, swelling, and stiffness caused by various arthritic conditions. It is applied in clinical settings marked by heightened patient distress, offering supportive therapeutic benefit to help patients cope more steadily with difficult episodes.

It is relevant in clinical settings that involve acute or unstable symptom patterns, such as the persistent pain of Osteoarthritis and Rheumatoid Arthritis, sudden attacks of Gouty Arthritis, or recurring phases like Primary Dysmenorrhea and Acute Migraine. The drug may also be used for managing symptoms related to systemic imbalance, such as reducing elevated body temperature (fever), and addressing localized postoperative inflammation.

“The medication is applied to ease the overall symptom burden, which supports patients during difficult episodes by easing distress.”

Quick Fact: Support for Joint Pain and Stiffness

This medication is applied in addressing Wood conditions where functional stability becomes affected, and may assist patients with chronic joint conditions in managing persistent symptoms like stiffness and tenderness that interfere with routine activities.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Diclofenac STADA?

This medicine's official eligibility is strictly governed by pre-existing conditions and population-specific restrictions documented by regulatory authorities (such as the EMA and FDA).

Contraindicated Populations (Absolute Ban)

Category	Official Regulatory Status
Cardiovascular Disease	Contraindicated in established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease [2.1, 2.5].
Hypersensitivity/Allergy	Contraindicated in patients with a known hypersensitivity to diclofenac, or a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs [1.3, 2.1].
Active GI Status	Contraindicated with active gastric or intestinal ulceration, bleeding, or perforation [1.2].
Surgical Status	Contraindicated for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery [1.3, 2.1].
Pregnancy Stage	Contraindicated in the third trimester of pregnancy (at or after 30 weeks gestation) [1.2, 3.7].

Age-Related and Conditional Eligibility

Age-Related Eligibility: Diclofenac STADA is generally approved for adults [2.4]. Use in children under 14 years is often not recommended or contraindicated for systemic and topical forms [1.4]. Elderly patients are permitted use but must be treated with particular caution and monitoring due to higher risk [2.4].
Organ Impairment: Patients with severe hepatic or renal failure are contraindicated [1.2]. Those with mild to moderate impairment must use the medicine with caution [2.4].
Reproductive Status: Use is generally avoided in women from 20 weeks of pregnancy onward [3.7]. While only small amounts pass into milk, use while breastfeeding is generally not recommended due to limited data [3.2].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of diclofenac is defined by documented pharmacokinetic (PK) changes and pharmacodynamic (PD) risks, according to official regulatory labeling.

Interacting Medicinal Products

Classification	Interacting Agents	Official Interaction Outcome
Anticoagulants/Antiplatelets	Warfarin, Aspirin (low-dose), SSRIs	Additive risk for serious bleeding or hemorrhage.
Antihypertensives/Diuretics	ACE Inhibitors, ARBs, Diuretics	Diminished antihypertensive or natriuretic effect; risk of renal function deterioration.
Exposure-Altering Agents	Voriconazole (CYP2C9 inhibitor)	Increases diclofenac plasma concentration (AUC and Cmax).
Toxicity Risk Agents	Methotrexate, Lithium, Digoxin	Increases serum concentrations of these drugs due to impaired clearance.

Restrictions and Constraints

Co-administration with other systemic NSAIDs or analgesic doses of aspirin is not generally recommended. A specific timing rule requires cautious co-administration with Methotrexate when administered within 24 hours of each other. The product is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Interaction severity can be heightened in elderly patients and in volume-depleted patients co-administering with antihypertensive medicines. Consumption of alcohol is documented as a factor that increases the risk for serious gastrointestinal bleeding.

Mechanism of Action

How Diclofenac STADA works

Targeting Enzymes and Inflammatory Mediators

The drug acts as an inhibitor of the Cyclooxygenase ( COX) enzymes (both COX-1 and COX-2). This action reduces the synthesis of prostaglandins, which are chemical mediators that influence the inflammatory response. By blocking this molecular step, the mechanism results in a reduction in mediator activity at the cellular and tissue levels, leading to fewer chemical signals that modulate local fluid accumulation.

Dampening Pain Signaling and Nerve Sensitivity

Diclofenac modulates neural signaling pathways both at the site of tissue damage and within the central nervous system, including the spinal cord. Reduced prostaglandins decrease the chemical modulation of pain-sensing nerves (nociceptors), while the drug's influence on various ion channels further dampens the transmission of signals. This mechanism modulates activity within the nociceptive pathways, leading to a decrease in the excitability of nerve endings.

Regulating Central Body Temperature

The drug engages mechanisms that regulate the body's thermoregulatory center in the brain (hypothalamus). Fever involves prostaglandins acting on this central thermostat; by inhibiting their production and action here, Diclofenac interferes with the central signaling that establishes an elevated body temperature set point.

Dosage and Administration Information

Official Administration Guidelines

Proper use of diclofenac must strictly adhere to established dosing and procedural instructions. The governing principle for all systemic use is to use the lowest effective dosage for the shortest duration necessary.

Administration Route	Standard Dosing and Frequency	Special Administration Instructions
Oral Tablets/Capsules	The recommended daily dose generally ranges from 100 mg to 150 mg (for chronic conditions), administered in two or three divided doses (e.g., b.i.d. or t.i.d.). Maximum daily dose is generally 150 mg or 200 mg, depending on the formulation.	Delayed-release and extended-release tablets must be swallowed whole without being crushed, broken, or chewed. They are typically taken with liquid, often with or after food.
Oral Powder for Solution	A single 50 mg dose is used for acute attacks; a second 50 mg dose may be taken if relief is insufficient after two hours, up to a 200 mg daily maximum.	The contents of the packet must be mixed with 30 to 60 mL of water only and consumed immediately on an empty stomach.
Injectable (IM/IV)	Maximum daily dose is 150 mg. Intramuscular (IM) injection is typically one 75 mg ampoule once or twice daily.	Parenteral administration is generally limited to two days; treatment should transition to oral or rectal forms thereafter. Intravenous (IV) administration requires dilution and buffering and must be infused over a specified period (e.g., 30 minutes to 2 hours), not given as an IV bolus.

Population Considerations: In older adults, the lowest effective dosage should be used. For children over 14 years of age, the recommended daily dose for certain forms is 75 mg to 100 mg in divided doses.

If a dose is missed, the guidance is to skip the missed dose if it is almost time for the next scheduled dose, and return to the regular schedule; do not double the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Diclofenac STADA

Evidence for use in Short-Term Pain and Inflammation

Studies have been conducted to understand research scenarios relevant in trials assessing short-term or episodic symptom patterns, such as temporary physical discomfort following injuries like sprains or strains. Research examined outcomes related to physical discomfort and daily functioning (or activity level) in studies exploring short-term changes over defined time intervals.

Research focusing on short-term symptom patterns was conducted during periods of increased symptom activity and describes patterns observed in the studies. Findings indicate that this research contributed to the broader evidence landscape. It is important to remember that study results reflect the specific conditions under which they were conducted.

Evidence for use in Chronic Pain Conditions

Studies were conducted in research settings involving conditions marked by functional limitations and characterized by fluctuating or episodic manifestations. Research in this area has explored research focusing on episodes where symptoms become more noticeable, particularly outcomes describing episodic or acute changes and patient-reported outcomes describing perceived discomfort.

The available research describes patterns related to conditions where symptoms may vary in intensity. However, data for long-term outcomes are not fully established, and evidence quality varies across studies examining outcomes related to systemic or functional imbalance over extended periods. Studies help show what has been observed so far, but comparative evidence is sometimes lacking.

Long-term studies and follow-up

Research focusing on long-term studies aims to understand what has been observed so far in patients over extended periods. Follow-up durations were limited in some studies, meaning there is limited information for long-term outcomes and the durability of response was not fully established.

Research in this area was applied in studies examining patient-reported experiences and outcomes capturing phases of heightened symptom activity. While some studies monitored responses over defined time intervals, certainty remains low regarding what has been observed over the longest durations. Research highlights what is known—and what is still uncertain—about studies observing responses over defined, extended time intervals.

Evidence in special populations

Research has explored studies that included certain groups of people, particularly older adults. Research also examined data derived from settings with varying symptom burdens or with certain existing health conditions. This evidence applies in studies examining patient-reported experiences relevant to those with fluctuating or unstable symptoms.

However, data for certain groups remain insufficient. For instance, evidence is limited or non-existent in areas such as children or pregnancy-related populations. Findings describe group patterns, not personal outcomes, and results apply only to the populations studied. Subgroup findings are uncertain, and data are still emerging for many of these special populations.

What is still uncertain about Diclofenac STADA

Despite the existing research, there are still areas where more information is needed. Evidence is limited in certain populations that have not been adequately studied. In some areas, findings were mixed, and certainty remains low.

The research provides context but not individual predictions, and research does not determine whether an individual will respond similarly to the patterns observed in the studies. The evidence contributes to the broader evidence landscape, but study results reflect the specific conditions under which they were conducted. Data are still emerging, and research is ongoing.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Diclofenac STADA (FAQ)

Q: How quickly should I expect Diclofenac STADA to start working for a headache?

According to official product information, specific formulations of diclofenac, such as those used for acute pain, can show measurable levels in the bloodstream in as quickly as 10 minutes. The active substance often reaches its highest concentration in the plasma around one hour after administration, but this can vary between individuals.

Q: How long does the pain relief from Diclofenac STADA usually last?

The time the active substance remains in the body is measured by its terminal half-life, which is approximately 1 to 2 hours for unchanged diclofenac in the plasma. The pain-relieving effects may sometimes persist beyond the half-life, with the exact duration of relief dependent on the specific product formulation.

Q: Are there any long-term side effects associated with regular Diclofenac STADA use?

Official regulatory warnings emphasize that the risk of serious adverse events may increase with the duration of use and may also be dose-dependent. These serious events include gastrointestinal issues and potentially fatal cardiovascular events, like heart attack or stroke. Official regulatory guidance emphasizes using the medication for the shortest duration necessary to minimize potential risks.

Q: Is Diclofenac STADA available over the counter, or is it prescription-only?

Oral forms of diclofenac are generally classified as prescription-only medicine (POM) in many regions due to potential cardiovascular risks. However, specific topical gel formulations (for skin application) may be available for purchase over-the-counter (OTC), depending on the country's specific regulations.

Q: Is there a risk of dependency or addiction with Diclofenac STADA?

As a Non-Steroidal Anti-Inflammatory Drug (NSAID), diclofenac is not typically categorized as a controlled substance by regulatory bodies. The product label does not carry explicit warnings for physical dependence or addiction.

Q: Can Diclofenac STADA affect sleep patterns?

Official safety data lists certain central nervous system effects as potential adverse reactions. These include reports of insomnia (difficulty sleeping) and dream abnormalities, which may relate to altered sleep patterns.

Q: What type of pain is Diclofenac STADA not effective for?

The drug is contraindicated (absolutely advised against) for use in treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. The medicine is intended only for the indications (types of pain and inflammation) for which it has been approved.

Q: What should I do if I notice unusual bruising while taking Diclofenac STADA?

Bruising, officially termed ecchymosis, is a documented adverse reaction related to potential hematologic (blood-related) issues. Regulatory guidance advises monitoring certain blood parameters in patients who show signs of hematologic toxicity, including any unexplained bleeding.

Q: Does Diclofenac STADA come in different forms (e.g., tablet, gel, injection)?

Yes, diclofenac is made available in several different dosage forms suitable for various routes of administration. These forms include oral tablets (including delayed-release), capsules, oral solution, topical gel/patch for localized application, and a solution for injection.

Q: Can taking Diclofenac STADA affect the results of blood tests?

Yes, regulatory product information notes that an increase in liver transaminases (enzymes measured in blood tests) is a common adverse reaction. Regulatory guidance suggests that liver and kidney functions may be monitored during long-term therapy.

Q: What research or studies support the use of Diclofenac STADA for arthritis?

Diclofenac is specifically indicated in the official labeling for managing the signs and symptoms of inflammatory conditions such as osteoarthritis and rheumatoid arthritis. These uses are supported by clinical studies summarized in the regulatory documents.

Q: Is it normal to feel dizzy or drowsy after taking Diclofenac STADA?

Dizziness is listed as a common adverse reaction, and drowsiness is also listed among occasional adverse experiences affecting the nervous system. Due to these potential effects, regulatory information advises caution when engaging in activities that require mental alertness.

Q: Why is Diclofenac STADA often prescribed for post-operative pain?

Specific formulations of diclofenac are indicated for the management of mild to moderate acute pain. This includes pain that occurs after certain surgical procedures, which reflects its established efficacy as a potent agent that reduces pain and inflammation.

Q: Are there specific foods I should avoid when taking Diclofenac STADA?

Regulatory documents do not list specific foods that must be avoided. However, the official information does note that taking oral diclofenac tablets with food can delay the rate of absorption and reduce the maximum amount of the drug that reaches the bloodstream.

Q: What is the maximum number of days a person should generally take Diclofenac STADA consecutively?

The overarching principle for all systemic use is to use the lowest effective dosage for the shortest duration possible to minimize risk. While some specific routes, like injection, are generally limited to two days, the appropriate total duration for oral use must be determined by a qualified healthcare professional to manage individual risk.

Q: Why is it important to take Diclofenac STADA exactly as prescribed?

Adherence to the prescribed dose and duration is emphasized. Official warnings state that using the lowest effective dosage for the shortest duration is the necessary protocol for minimizing the potential risk of serious adverse events, including cardiovascular and gastrointestinal complications.

Q: Is Diclofenac STADA suitable for treating menstrual pain?

Yes, official product information for certain forms of diclofenac indicates that the medicine is indicated for the treatment of pain associated with menstrual cramps.

Q: What happens in the body when Diclofenac STADA is absorbed?

After administration, diclofenac is completely absorbed from the gastrointestinal tract. However, due to its breakdown by the liver (a process called 'first-pass metabolism'), only about 50% of the initial absorbed dose becomes fully available to circulate throughout the body.

Q: Can Diclofenac STADA affect kidney function over time?

Official warnings state that the long-term use of NSAIDs, including diclofenac, has been linked to the risk of renal injury and changes in the kidneys. Official warnings note that particular caution is advised in regulatory labeling for individuals with compromised kidney function or dehydration.

Q: Is it better to take Diclofenac STADA in the morning or at night?

General dosing is typically in divided doses throughout the day (two or three times daily). For certain specific conditions, such as ankylosing spondylitis, the official product information notes that an extra dose may sometimes be recommended at bedtime if necessary to manage symptoms.

Q: Does Diclofenac STADA have a generic equivalent?

Yes, the active ingredient, diclofenac, is a widely established compound and is available in various generic formulations.

Q: Is it safe to drive after taking Diclofenac STADA?

Because adverse reactions such as dizziness, drowsiness, and confusion have been reported, patients should be aware of these potential effects. Regulatory information advises that individuals should avoid driving or operating complex machinery if they experience side effects that impair their mental alertness or motor skills.

Q: What is the difference in action between a topical Diclofenac STADA preparation and an oral one?

Oral forms are intended to work systemically, meaning they affect the entire body after being swallowed. Topical preparations (like gels) are applied to the skin and are primarily intended to provide localized relief at the site of application, resulting in significantly lower systemic exposure.

Q: Does Diclofenac STADA interact with common cold or flu medicines?

Official guidance advises against taking diclofenac concurrently with other systemic NSAIDs or analgesic doses of aspirin. Many common cold and flu relief medications contain one of these ingredients, which could lead to an increased risk of adverse events.

Q: What steps can be taken to minimize the stomach side effects of Diclofenac STADA?

Official product information states that the use of the lowest effective dosage for the shortest duration possible is the primary method to minimize risks. Taking some oral forms with or after food may help reduce irritation, and some specific formulations are co-packaged with a stomach protective agent.

Q: What is the half-life of Diclofenac STADA in the human body?

The terminal half-life of unchanged diclofenac in the human body is approximately 1 to 2 hours. This is a measure of the time it takes for the concentration of the drug in the plasma to be reduced by half.

How should Diclofenac STADA be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Diclofenac STADA to maintain product integrity and ensure safety.

Requirement Area	Official Instructions
Temperature & Environment	Store at room temperature, away from heat, moisture, and direct light; tablet forms should generally not be stored above 25 C, and the product must be kept from freezing.
Packaging & Stability	Always store the medicine in its original, closed container. Do not use the medicine after the expiry date (EXP) stated on the packaging; some topical forms may have a limited shelf-life once opened.
Safety & Disposal	Keep out of the sight and reach of children. Do not dispose of expired or unused product by throwing it into wastewater or household waste. Patients are instructed to ask a pharmacist how to properly discard medicines no longer needed, in accordance with environmental protection measures.

Diclofenac STADA